Menu

With a unique combination of machine learning & imaging technology, PatenSee democratizes best clinical practices

algorithms to identify
emerging patterns (“fingerprints”) of developing stenosis

With a unique combination of machine learning & imaging technology, PatenSee democratizes best clinical practices

Algorithms to identify
emerging patterns (“fingerprints”) of developing stenosis

PatenSee’s System

                                                                             Multi-modal imaging technologies, AI and machine learning

Look

Subdermal imaging of collateral veins

3D imaging – observes the status of the fistula

Listen & Feel

Listens optically (no-contact) – detects the change in pulsatility and vibration, along with statoscope-like features

Machine Learning

Provides a model simulating the full status of the patient’s vascular access, with early detection of a clinically-meaningful stenosis

PatenSee’s Solution

Expedites and Automizes

Delivers in 1 minute what the standard of care produces in 7 minutes.

Increases Accuracy

The patient’s fistula is checked by the same PatenSee 3D imaging solution every time, rather than subjective physical examinations.

Democratizes Treatment

The AI driven technology makes best clinical practices universally available.

Streamlines the Process

Back To Top
© Patensee 2024
Powered by: SPInc

PatenSee is an emerging, clinical-stage, startup company with a novel, contactless imaging device for the early detection of vascular access complications in hemodialysis patients. The technology uses a unique data stream to mimic a best practice, physical examination. PatenSee recently signed a clinical collaboration agreement with Fresenius Medical Care, following the completion of a POC clinical trial with very promising results.


PatenSee is a portfolio company of MEDX Xelerator, a medical device incubator backed by Boston Scientific, Sheba Medical Center, MEDX Ventures Group, Consensus Business Group (CBG), West Pharmaceuticals and The Portland Trust.